Lost cost savings to the NHS in England due to the delayed entry of multiple generic low-dose transdermal buprenorphine: a case scenario analysis

OBJECTIVE: Originator pharmaceutical companies prolonging the patent of a medicine prevents rivals’ entry to the market and competition. As the entry of generic alternatives usually results in price reduction, any delay in their entry potentially deprives the National Health Service (NHS) of much-ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Chapman, Stephen Robert, Aladul, Mohammed Ibrahim, Fitzpatrick, Raymond William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Health Policy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688687/
https://www.ncbi.nlm.nih.gov/pubmed/31375605
http://dx.doi.org/10.1136/bmjopen-2018-026817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688687/
https://www.ncbi.nlm.nih.gov/pubmed/31375605
http://dx.doi.org/10.1136/bmjopen-2018-026817

Ejemplares similares